Tyrosine kinase inhibitors (TKI) induce prolonged remission in CML, and therapy discontinuation is an accepted approach to patients with reduction in Bcr–abl transcripts of four logs or greater. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.